Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AnaptysBio, Inc. (ANAB)
USD56.02
-6.49 (-10.38%)
US NASDAQ Healthcare Biotechnology
Address
10770 Wateridge Circle 92121-5801
San Diego, CA, US
San Diego, CA, US
CEO
Daniel Faga
Website
anaptysbio.com
IPO
2017-01-26
CIK 1370053 ISIN US0327241065
Description
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD56.02
-6.49 (-10.38%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
665.4K
Beta
0.41
Float Shares
40.29M
Free Float %
93.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.45% | -1.43% | +40.34% | +79.18% | +197.28% | +102.91% | +391.24% | +405.63% | +286.67% | +478.82% | +478.82% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (22 ratings, all time)
Buy
Price Targets & DCF
Current price
56.02
Low
50.00
-10.7%
Consensus
77.29
+38.0%
Median
66.00
+17.8%
High
140.00
+149.9%
Ratings Trend (MoM)
91% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | -2 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
72.50
+29.4%
|
| Last Quarter | 5 |
69.20
+23.5%
|
| Last Year | 16 |
69.38
+23.8%
|
| All Time | 28 |
59.68
+6.5%
|
Quality scores
Altman Z-Score
4.06
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+157.0% ★ Q1'26: -8.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+91.0% ★ Q1'26: -43.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-47.1% Q1'26: -101.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+20.4% ★ Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+10.4% Q1'26: -6.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.28× ★ Q1'26: -0.10× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
16.68M
est: 16.04M (+4.0%)
|
10.00M
est: 7.78M (+28.5%)
|
5.00M
est: 4.18M (+19.8%)
|
8.00M
est: 7.00M (+14.3%)
|
75.00M
est: 95.00M (-21.1%)
|
63.18M
est: 63.17M (+0.0%)
|
10.29M
est: 9.05M (+13.6%)
|
17.16M
est: 30.47M (-43.7%)
|
91.28M
est: 55.91M (+63.3%)
|
234.60M
est: 205.27M (+14.3%)
|
100.64M
89.46M – 118.74M
-51.0% YoY
|
169.82M
126.72M – 216.44M
+68.7% YoY
|
299.19M
292.21M – 306.17M
+76.2% YoY
|
362.14M
270.23M – 461.55M
+21.0% YoY
|
477.11M
356.02M – 608.08M
+31.7% YoY
|
| EBITDA |
-3.57M
est: -13.28M (+73.1%)
|
-28.11M
est: -6.44M (-336.3%)
|
-59.88M
est: -68.32M (+12.4%)
|
-95.93M
est: -5.80M (-1,555.1%)
|
-19.37M
est: -13.18M (-46.9%)
|
-55.71M
est: -52.30M (-6.5%)
|
-105.26M
est: -16.19M (-550.0%)
|
-156.42M
est: -22.35M (-599.8%)
|
-92.74M
est: -41.01M (-126.1%)
|
50.32M
est: -150.56M (+133.4%)
|
-73.81M
-87.09M – -65.61M
+51.0% YoY
|
-124.56M
-158.75M – -92.94M
-68.7% YoY
|
-219.45M
-224.57M – -214.32M
-76.2% YoY
|
-265.62M
-338.53M – -198.20M
-21.0% YoY
|
-349.94M
-446.00M – -261.13M
-31.7% YoY
|
| EBIT |
-3.80M
est: -13.41M (+71.7%)
|
-28.30M
est: -6.51M (-334.9%)
|
-60.20M
est: -70.09M (+14.1%)
|
-96.45M
est: -5.85M (-1,547.9%)
|
-19.93M
est: -16.85M (-18.3%)
|
-57.80M
est: -52.82M (-9.4%)
|
-107.59M
est: -19.84M (-442.3%)
|
-157.07M
est: -22.62M (-594.5%)
|
-95.14M
est: -41.50M (-129.3%)
|
47.90M
est: -152.34M (+131.4%)
|
-74.69M
-88.12M – -66.39M
+51.0% YoY
|
-126.03M
-160.63M – -94.04M
-68.7% YoY
|
-222.04M
-227.22M – -216.86M
-76.2% YoY
|
-268.76M
-342.53M – -200.55M
-21.0% YoY
|
-354.08M
-451.28M – -264.22M
-31.7% YoY
|
| Net Income |
-4.26M
est: -3.60M (-18.5%)
|
-30.07M
est: -46.97M (+36.0%)
|
-61.66M
est: -64.27M (+4.1%)
|
-97.34M
est: -115.01M (+15.4%)
|
-19.93M
est: -12.30M (-62.0%)
|
-57.80M
est: -52.01M (-11.1%)
|
-128.72M
est: -26.58M (-384.3%)
|
-163.62M
est: -170.12M (+3.8%)
|
-145.23M
est: -124.61M (-16.5%)
|
-13.23M
est: -13.23M (+0.0%)
|
-52.87M
-92.08M – -13.66M
-299.5% YoY
|
-64.41M
-103.20M – -25.62M
-21.8% YoY
|
201.15M
-93.11M – 385.42M
+412.3% YoY
|
173.58M
116.31M – 235.52M
-13.7% YoY
|
228.15M
152.88M – 309.56M
+31.4% YoY
|
| SGA |
4.29M
est: 22.66M (-81.1%)
|
9.34M
est: 10.99M (-15.0%)
|
15.53M
est: 5.90M (+163.3%)
|
16.09M
est: 9.89M (+62.8%)
|
18.85M
est: 19.89M (-5.2%)
|
21.49M
est: 89.23M (-75.9%)
|
36.64M
est: 12.79M (+186.6%)
|
41.95M
est: 42.83M (-2.1%)
|
42.39M
est: 78.59M (-46.1%)
|
50.74M
est: 288.52M (-82.4%)
|
141.45M
125.74M – 166.89M
-51.0% YoY
|
238.69M
178.11M – 304.21M
+68.7% YoY
|
420.53M
410.72M – 430.34M
+76.2% YoY
|
509.01M
379.83M – 648.73M
+21.0% YoY
|
670.61M
500.41M – 854.68M
+31.7% YoY
|
| EPS |
-0.23
est: -0.13 (-81.6%)
|
-1.52
est: -1.66 (+8.2%)
|
-2.50
est: -2.85 (+12.4%)
|
-3.60
est: -4.05 (+11.2%)
|
-0.73
est: 0.04 (-1,817.6%)
|
-2.11
est: -1.83 (-15.1%)
|
-4.57
est: -4.53 (-1.0%)
|
-6.08
est: -6.34 (+4.1%)
|
-5.12
est: -4.06 (-26.2%)
|
-0.46
est: -0.96 (+52.3%)
|
-2.10
-2.94 – -0.44
-117.6% YoY
|
-2.34
-3.29 – -0.82
-11.7% YoY
|
5.33
-2.97 – 12.30
+327.6% YoY
|
5.54
3.71 – 7.51
+3.8% YoY
|
7.28
4.88 – 9.88
+31.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | Piper Sandler | Overweight | Overweight | Maintain |
| 2026-04-28 | Leerink Partners | Outperform | Outperform | Maintain |
| 2026-04-22 | Barclays | Overweight | Overweight | Maintain |
| 2026-04-21 | UBS | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
46.57M
OE per share TTM
1.33
Owner's Yield
2.47%
Maintenance CapEx ratio
24.70%
Maint CapEx / Avg PPE
18.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
71
Total invested
178.24M
Insider transactions (90d)
5
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 2.87M | 10.51% | — | — | 2.87M | — | IN | Delaware | 2024-07-10 | ↗ |
| 2 | FMR LLC | 2.87M | 10.51% | 2.87M | — | 2.87M | — | HC | Delaware | 2024-07-10 | ↗ |
| 3 | James N. Topper | 1.92M | 7.00% | 80.8K | 1.84M | 80.8K | 1.84M | IN | Delaware | 2024-05-06 | ↗ |
| 4 | Patrick J. Heron | 1.85M | 6.80% | 9.1K | 1.84M | 9.1K | 1.84M | IN | Delaware | 2024-05-06 | ↗ |
| 5 | Brian Morfitt | 905.1K | 3.30% | 5.4K | 899.7K | 5.4K | 899.7K | IN | Delaware | 2024-05-06 | ↗ |
| 6 | Nathan Every | 904.3K | 3.30% | 4.6K | 899.7K | 4.6K | 899.7K | IN | Delaware | 2024-05-06 | ↗ |
| 7 | Alan Frazier | 899.7K | 3.30% | — | 899.7K | — | 899.7K | IN | Delaware | 2024-05-06 | ↗ |
| 8 | FHM VII, L.L.C. | 899.7K | 3.30% | — | 899.7K | — | 899.7K | OO | Delaware | 2024-05-06 | ↗ |
| 9 | FHM VII, L.P. | 899.7K | 3.30% | — | 899.7K | — | 899.7K | PN | Delaware | 2024-05-06 | ↗ |
| 10 | Nader Naini | 899.7K | 3.30% | — | 899.7K | — | 899.7K | IN | Delaware | 2024-05-06 | ↗ |
| 11 | Frazier Healthcare VII, L.P. | 700.2K | 2.60% | — | 700.2K | — | 700.2K | PN | Delaware | 2024-05-06 | ↗ |
| 12 | Albert Cha | 680.1K | 2.50% | — | 680.1K | — | 680.1K | IN | Delaware | 2024-05-06 | ↗ |
| 13 | James Brush | 680.1K | 2.50% | — | 680.1K | — | 680.1K | IN | Delaware | 2024-05-06 | ↗ |
| 14 | FHMLSP, L.L.C. | 611.7K | 2.20% | — | 611.7K | — | 611.7K | OO | Delaware | 2024-05-06 | ↗ |
| 15 | FHMLSP, L.P. | 611.7K | 2.20% | — | 611.7K | — | 611.7K | PN | Delaware | 2024-05-06 | ↗ |
| 16 | Frazier Life Sciences Public Fund, L.P. | 611.7K | 2.20% | — | 611.7K | — | 611.7K | PN | Delaware | 2024-05-06 | ↗ |
| 17 | Frazier Healthcare VII-A, L.P. | 199.5K | 0.70% | — | 199.5K | — | 199.5K | PN | Delaware | 2024-05-06 | ↗ |
| 18 | Daniel Estes | 174.8K | 0.60% | — | 174.8K | — | 174.8K | IN | Delaware | 2024-05-06 | ↗ |
| 19 | FHMLS XI, L.L.C. | 174.8K | 0.60% | — | 174.8K | — | 174.8K | OO | Delaware | 2024-05-06 | ↗ |
| 20 | FHMLS XI, L.P. | 174.8K | 0.60% | — | 174.8K | — | 174.8K | PN | Delaware | 2024-05-06 | ↗ |
| 21 | Frazier Life Sciences XI, L.P. | 174.8K | 0.60% | — | 174.8K | — | 174.8K | PN | Delaware | 2024-05-06 | ↗ |
| 22 | FHMLS X, L.L.C. | 81.8K | 0.30% | — | 81.8K | — | 81.8K | OO | Delaware | 2024-05-06 | ↗ |
| 23 | FHMLS X, L.P. | 81.8K | 0.30% | — | 81.8K | — | 81.8K | PN | Delaware | 2024-05-06 | ↗ |
| 24 | Frazier Life Sciences X, L.P. | 81.8K | 0.30% | — | 81.8K | — | 81.8K | PN | Delaware | 2024-05-06 | ↗ |
| 25 | FHMLSP Overage, L.L.C. | 68.4K | 0.30% | — | 68.4K | — | 68.4K | OO | Delaware | 2024-05-06 | ↗ |
| 26 | FHMLSP Overage, L.P. | 68.4K | 0.30% | — | 68.4K | — | 68.4K | PN | Delaware | 2024-05-06 | ↗ |
| 27 | Frazier Life Sciences Public Overage Fund, L.P. | 68.4K | 0.30% | — | 68.4K | — | 68.4K | PN | Delaware | 2024-05-06 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
71
-112 vs prev Q
New positions
21
Closed positions
128
Increased
35
Reduced
19
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 93.7K +93.7K (+100.0%) | 4.54B +4.5B (+100.0%) | 0.32% +0.323 pp | 0.01% +0.007 pp | USD48.48 +0.0% | 1 qtrs NEW |
| 2 | ECOR1 CAPITAL, LLC | 7.88M +— (+0.0%) | 382.03M +140.7M (+58.3%) | 27.11% -0.239 pp | 17.33% +5.754 pp | USD19.63 +147.0% | 25 qtrs — |
| 3 | POINT72 ASSET MANAGEMENT, L.P. | 1.93M -332.6K (-14.7%) | 93.71M +24.3M (+35.1%) | 6.65% -1.213 pp | 0.10% -0.011 pp | USD18.75 +158.6% | 17 qtrs — |
| 4 | BLACKROCK, INC. | 1.73M +12.1K (+0.7%) | 84.09M +31.3M (+59.4%) | 5.97% -0.011 pp | 0.00% +0.001 pp | USD30.70 +57.9% | 6 qtrs — |
| 5 | VANGUARD GROUP INC | 1.54M +67.0K (+4.5%) | 74.85M +29.6M (+65.5%) | 5.31% +0.186 pp | 0.00% +0.000 pp | USD52.71 -8.0% | 36 qtrs — |
| 6 | TANG CAPITAL MANAGEMENT LLC | 1.33M -1.6K (-0.1%) | 64.58M +23.7M (+58.1%) | 4.58% -0.046 pp | 3.19% +1.618 pp | USD16.72 +190.0% | 25 qtrs — |
| 7 | STATE STREET CORP | 1.05M +180.0K (+20.6%) | 51.07M +24.3M (+91.0%) | 3.62% +0.593 pp | 0.00% +0.001 pp | USD27.26 +77.8% | 36 qtrs — |
| 8 | MORGAN STANLEY | 1.03M -521.7K (-33.5%) | 50.16M +2.5M (+5.3%) | 3.56% -1.842 pp | 0.00% +0.000 pp | USD21.94 +121.0% | 36 qtrs — |
| 9 | SANOFI | 821.9K +— (+0.0%) | 39.85M +14.7M (+58.3%) | 2.83% -0.025 pp | 12.84% +3.170 pp | USD13.24 +266.2% | 5 qtrs — |
| 10 | MILLENNIUM MANAGEMENT LLC | 813.6K -705.7K (-46.4%) | 39.44M -7.1M (-15.2%) | 2.80% -2.474 pp | 0.02% -0.003 pp | USD29.51 +64.3% | 36 qtrs — |
| 11 | PALO ALTO INVESTORS LP | 690.0K +16.5K (+2.5%) | 33.45M +12.8M (+62.2%) | 2.37% +0.036 pp | 4.66% +0.841 pp | USD19.74 +145.6% | 22 qtrs — |
| 12 | D. E. SHAW & CO., INC. | 670.3K +320.9K (+91.9%) | 32.50M +21.8M (+203.8%) | 2.31% +1.094 pp | 0.02% +0.012 pp | USD37.99 +27.6% | 25 qtrs — |
| 13 | 683 CAPITAL MANAGEMENT, LLC | 648.1K +101.1K (+18.5%) | 31.42M +14.7M (+87.6%) | 2.23% +0.331 pp | 1.37% +0.492 pp | USD25.82 +87.8% | 4 qtrs — |
| 14 | FIRST LIGHT ASSET MANAGEMENT, LLC | 646.2K -343.9K (-34.7%) | 31.33M +1.0M (+3.3%) | 2.22% -1.213 pp | 2.40% -0.463 pp | USD19.28 +151.5% | 11 qtrs — |
| 15 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 559.7K +189.3K (+51.1%) | 27.14M +15.8M (+139.2%) | 1.93% +0.640 pp | 0.02% +0.009 pp | USD34.39 +41.0% | 3 qtrs — |
| 16 | WOODLINE PARTNERS LP | 501.0K +— (+0.0%) | 24.29M +8.9M (+58.3%) | 1.72% -0.015 pp | 0.09% +0.022 pp | USD23.41 +107.1% | 20 qtrs — |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 469.5K -4.1K (-0.9%) | 22.77M +8.3M (+57.0%) | 1.62% -0.029 pp | 0.00% +0.001 pp | USD46.73 +3.7% | 36 qtrs — |
| 18 | AFFINITY ASSET ADVISORS, LLC | 444.7K +444.7K (+100.0%) | 21.56M +21.6M (+100.0%) | 1.53% +1.530 pp | 1.23% +1.228 pp | USD48.48 +0.0% | 1 qtrs NEW |
| 19 | GOLDMAN SACHS GROUP INC | 398.9K +69.1K (+20.9%) | 19.34M +9.2M (+91.5%) | 1.37% +0.228 pp | 0.00% +0.001 pp | USD29.97 +61.8% | 35 qtrs — |
| 20 | TWO SIGMA ADVISERS, LP | 356.7K -17.0K (-4.5%) | 17.29M +5.9M (+51.1%) | 1.23% -0.070 pp | 0.03% +0.011 pp | USD23.59 +105.5% | 32 qtrs — |
| 21 | NUVEEN, LLC | 316.7K -22.6K (-6.7%) | 15.35M +5.0M (+47.8%) | 1.09% -0.088 pp | 0.00% +0.001 pp | USD21.99 +120.5% | 4 qtrs — |
| 22 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 304.5K +92.8K (+43.8%) | 14.76M +8.3M (+127.7%) | 1.05% +0.313 pp | 0.00% +0.001 pp | USD32.57 +48.8% | 6 qtrs — |
| 23 | FEDERATED HERMES, INC. | 299.4K +106.1K (+54.9%) | 14.52M +8.6M (+145.2%) | 1.03% +0.359 pp | 0.02% +0.014 pp | USD37.02 +31.0% | 36 qtrs — |
| 24 | SOFINNOVA INVESTMENTS, INC. | 287.7K +33.4K (+13.1%) | 13.95M +6.2M (+79.1%) | 0.99% +0.107 pp | 0.60% +0.176 pp | USD21.52 +125.3% | 5 qtrs — |
| 25 | TWO SIGMA INVESTMENTS, LP | 256.6K +215.0 (+0.1%) | 12.44M +4.6M (+58.5%) | 0.88% -0.007 pp | 0.02% +0.006 pp | USD22.05 +119.9% | 34 qtrs — |
| 26 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 229.1K +219.8K (+2,358.3%) | 11.11M +10.8M (+3,792.2%) | 0.79% +0.756 pp | 0.04% +0.038 pp | USD47.75 +1.5% | 6 qtrs — |
| 27 | ENSIGN PEAK ADVISORS, INC | 215.5K +— (+0.0%) | 10.45M +3.8M (+58.3%) | 0.74% -0.007 pp | 0.02% +0.008 pp | USD17.76 +173.0% | 18 qtrs — |
| 28 | CAPTION MANAGEMENT, LLC | 200.0K +200.0K (+100.0%) | 9.70M +9.7M (+100.0%) | 0.69% +0.688 pp | 0.07% +0.067 pp | USD48.48 +0.0% | 1 qtrs NEW |
| 29 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 198.7K -7.8K (-3.8%) | 9.63M +3.3M (+52.4%) | 0.68% -0.033 pp | 0.00% +0.001 pp | USD49.89 -2.8% | 36 qtrs — |
| 30 | NORTHERN TRUST CORP | 181.9K -13.7K (-7.0%) | 8.82M +2.8M (+47.3%) | 0.63% -0.053 pp | 0.00% +0.000 pp | USD40.22 +20.5% | 36 qtrs — |
| 31 | BNP PARIBAS ARBITRAGE, SNC | 164.8K +59.2K (+56.0%) | 7.99M +4.8M (+147.0%) | 0.57% +0.200 pp | 0.00% +0.002 pp | USD37.06 +30.8% | 35 qtrs — |
| 32 | SQUAREPOINT OPS LLC | 160.7K +92.7K (+136.3%) | 7.79M +5.7M (+274.2%) | 0.55% +0.317 pp | 0.01% +0.006 pp | USD37.36 +29.8% | 15 qtrs — |
| 33 | SOLEUS CAPITAL MANAGEMENT, L.P. | 135.0K -491.0K (-78.4%) | 6.54M -12.6M (-65.9%) | 0.46% -1.709 pp | 0.24% -0.724 pp | USD24.84 +95.2% | 5 qtrs — |
| 34 | BANK OF AMERICA CORP /DE/ | 130.8K +3.5K (+2.8%) | 6.34M +2.4M (+62.7%) | 0.45% +0.008 pp | 0.00% +0.000 pp | USD19.53 +148.2% | 36 qtrs — |
| 35 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 125.9K -21.9K (-14.8%) | 6.10M +1.6M (+34.8%) | 0.43% -0.080 pp | 0.26% +0.076 pp | USD16.45 +194.7% | 5 qtrs — |
| 36 | INVESCO LTD. | 124.0K +81.6K (+192.6%) | 6.01M +4.7M (+363.3%) | 0.43% +0.280 pp | 0.00% +0.001 pp | USD40.08 +21.0% | 28 qtrs — |
| 37 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 122.5K +122.5K (+100.0%) | 5.94M +5.9M (+100.0%) | 0.42% +0.421 pp | 0.02% +0.016 pp | USD48.48 +0.0% | 1 qtrs NEW |
| 38 | EVERSEPT PARTNERS, LP | 120.9K +120.9K (+100.0%) | 5.86M +5.9M (+100.0%) | 0.42% +0.416 pp | 0.30% +0.295 pp | USD48.48 +0.0% | 1 qtrs NEW |
| 39 | JUMP FINANCIAL, LLC | 120.2K +38.1K (+46.5%) | 5.83M +3.3M (+131.9%) | 0.41% +0.129 pp | 0.07% +0.042 pp | USD36.29 +33.6% | 2 qtrs — |
| 40 | VICTORY CAPITAL MANAGEMENT INC | 110.6K -93.5K (-45.8%) | 5.36M -887.1K (-14.2%) | 0.38% -0.328 pp | 0.00% -0.001 pp | USD24.22 +100.2% | 10 qtrs — |
| 41 | CITADEL ADVISORS LLC | 109.5K +83.0K (+313.5%) | 5.31M +4.5M (+554.6%) | 0.38% +0.285 pp | 0.00% +0.001 pp | USD42.40 +14.3% | 16 qtrs — |
| 42 | QUBE RESEARCH & TECHNOLOGIES LTD | 109.0K +109.0K (+100.0%) | 5.28M +5.3M (+100.0%) | 0.37% +0.375 pp | 0.01% +0.005 pp | USD48.48 +0.0% | 1 qtrs NEW |
| 43 | JANE STREET GROUP, LLC | 105.2K +72.6K (+222.7%) | 5.10M +4.1M (+410.9%) | 0.36% +0.249 pp | 0.00% +0.001 pp | USD42.07 +15.2% | 6 qtrs — |
| 44 | HIGHMARK WEALTH MANAGEMENT LLC | 94.1K -41.0K (-30.4%) | 4.56M +138.0K (+3.1%) | 0.32% -0.145 pp | 1.86% -0.088 pp | USD19.92 +143.4% | 4 qtrs — |
| 45 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 83.3K +56.8K (+214.4%) | 4.04M +3.2M (+397.8%) | 0.29% +0.195 pp | 0.03% +0.023 pp | USD39.45 +22.9% | 19 qtrs — |
| 46 | RENAISSANCE TECHNOLOGIES LLC | 76.3K -47.0K (-38.1%) | 3.70M -76.4K (-2.0%) | 0.26% -0.165 pp | 0.01% +0.001 pp | USD22.03 +120.1% | 12 qtrs — |
| 47 | CITIGROUP INC | 73.5K +2.9K (+4.1%) | 3.56M +1.4M (+64.9%) | 0.25% +0.008 pp | 0.00% +0.001 pp | USD19.68 +146.3% | 36 qtrs — |
| 48 | HRT FINANCIAL LP | 70.1K +45.1K (+180.2%) | 3.40M +2.6M (+343.7%) | 0.24% +0.154 pp | 0.01% +0.008 pp | USD42.11 +15.1% | 6 qtrs — |
| 49 | UBS GROUP AG | 70.0K -5.2K (-6.9%) | 3.40M +1.1M (+47.3%) | 0.24% -0.020 pp | 0.00% +0.000 pp | USD20.91 +131.9% | 36 qtrs — |
| 50 | WELLINGTON MANAGEMENT GROUP LLP | 61.2K -5.5K (-8.3%) | 2.97M +923.0K (+45.2%) | 0.21% -0.021 pp | 0.00% +0.000 pp | USD21.61 +124.3% | 8 qtrs — |
| 51 | BARCLAYS PLC | 59.7K +15.4K (+34.7%) | 2.89M +1.4M (+94.9%) | 0.21% +0.052 pp | 0.00% +0.000 pp | USD28.75 +68.6% | 36 qtrs — |
| 52 | TREXQUANT INVESTMENT LP | 58.8K -53.0K (-47.4%) | 2.85M -571.6K (-16.7%) | 0.20% -0.186 pp | 0.03% -0.010 pp | USD22.86 +112.1% | 12 qtrs — |
| 53 | FISHER ASSET MANAGEMENT, LLC | 56.6K -2.3K (-3.9%) | 2.74M +939.4K (+52.1%) | 0.19% -0.010 pp | 0.00% +0.000 pp | USD27.29 +77.6% | 18 qtrs — |
| 54 | PENSERRA CAPITAL MANAGEMENT LLC | 56.4K +56.4K (+100.0%) | 2.73M +2.7M (+100.0%) | 0.19% +0.194 pp | 0.03% +0.032 pp | USD48.48 +0.0% | 1 qtrs NEW |
| 55 | BANK OF NEW YORK MELLON CORP | 55.3K -1.7K (-3.0%) | 2.68M +936.9K (+53.6%) | 0.19% -0.008 pp | 0.00% +0.000 pp | USD52.85 -8.3% | 36 qtrs — |
| 56 | JACOBS LEVY EQUITY MANAGEMENT, INC | 55.1K -323.4K (-85.4%) | 2.67M -8.9M (-77.0%) | 0.19% -1.124 pp | 0.01% -0.036 pp | USD22.22 +118.2% | 12 qtrs — |
| 57 | MOODY ALDRICH PARTNERS LLC | 47.6K -2.3K (-4.6%) | 2.31M +780.3K (+51.1%) | 0.16% -0.009 pp | 0.43% +0.141 pp | USD18.59 +160.8% | 4 qtrs — |
| 58 | BLEAKLEY FINANCIAL GROUP, LLC | 43.5K +3.6K (+8.9%) | 2.11M +886.9K (+72.4%) | 0.15% +0.011 pp | 0.04% +0.008 pp | USD24.82 +95.3% | 3 qtrs — |
| 59 | PDT PARTNERS, LLC | 43.0K +— (+0.0%) | 2.08M +768.0K (+58.3%) | 0.15% -0.001 pp | 0.14% +0.052 pp | USD18.59 +160.8% | 8 qtrs — |
| 60 | CREDIT AGRICOLE S A | 40.0K +40.0K (+100.0%) | 1.94M +1.9M (+100.0%) | 0.14% +0.138 pp | 0.00% +0.004 pp | USD48.48 +0.0% | 1 qtrs NEW |
| 61 | XTX TOPCO LTD | 38.6K +20.5K (+113.3%) | 1.87M +1.3M (+237.8%) | 0.13% +0.070 pp | 0.05% +0.020 pp | USD36.16 +34.1% | 9 qtrs — |
| 62 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 35.9K +500.0 (+1.4%) | 1.74M +657.3K (+60.6%) | 0.12% +0.001 pp | 0.03% +0.010 pp | USD23.19 +109.1% | 3 qtrs — |
| 63 | RAFFERTY ASSET MANAGEMENT, LLC | 35.3K +5.2K (+17.4%) | 1.71M +790.6K (+85.8%) | 0.12% +0.017 pp | 0.01% +0.003 pp | USD23.41 +107.1% | 28 qtrs — |
| 64 | DCF ADVISERS, LLC | 35.3K -12.8K (-26.6%) | 1.71M +239.2K (+16.3%) | 0.12% -0.045 pp | 0.46% -0.014 pp | USD19.58 +147.6% | 4 qtrs — |
| 65 | Y-INTERCEPT (HONG KONG) LTD | 33.1K +33.1K (+100.0%) | 1.60M +1.6M (+100.0%) | 0.11% +0.114 pp | 0.04% +0.036 pp | USD48.48 +0.0% | 1 qtrs NEW |
| 66 | ALLIANCEBERNSTEIN L.P. | 30.5K +— (+0.0%) | 1.48M +545.1K (+58.3%) | 0.11% -0.001 pp | 0.00% +0.000 pp | USD30.38 +59.6% | 33 qtrs — |
| 67 | UBS ASSET MANAGEMENT AMERICAS INC | 30.5K -2.8K (-8.3%) | 1.48M +460.3K (+45.2%) | 0.11% -0.011 pp | 0.00% +0.000 pp | USD22.88 +111.9% | 33 qtrs — |
| 68 | ADVISOR GROUP HOLDINGS, INC. | 27.7K +25.9K (+1,427.4%) | 1.34M +1.3M (+2,317.9%) | 0.10% +0.089 pp | 0.00% +0.002 pp | USD46.76 +3.7% | 9 qtrs — |
| 69 | SWISS NATIONAL BANK | 27.6K -800.0 (-2.8%) | 1.34M +468.4K (+53.9%) | 0.10% -0.004 pp | 0.00% +0.000 pp | USD39.33 +23.3% | 35 qtrs — |
| 70 | FMR LLC | 27.1K -26.1K (-49.0%) | 1.31M -313.6K (-19.3%) | 0.09% -0.091 pp | 0.00% +0.000 pp | USD25.98 +86.6% | 34 qtrs — |
| 71 | AQR CAPITAL MANAGEMENT LLC | 26.3K +135.0 (+0.5%) | 1.28M +474.0K (+59.1%) | 0.09% 0.000 pp | 0.00% +0.000 pp | USD24.60 +97.1% | 9 qtrs — |
| 72 | PRICE T ROWE ASSOCIATES INC /MD/ | 26.0K -273.3K (-91.3%) | 1.26M -7.9M (-86.2%) | 0.09% -0.949 pp | 0.00% -0.001 pp | USD29.35 +65.2% | 10 qtrs — |
| 73 | CAMPBELL & CO INVESTMENT ADVISER LLC | 25.4K +7.1K (+38.8%) | 1.23M +670.1K (+119.7%) | 0.09% +0.024 pp | 0.06% +0.017 pp | USD35.61 +36.1% | 2 qtrs — |
| 74 | HEADLANDS TECHNOLOGIES LLC | 25.3K +25.3K (+100.0%) | 1.23M +1.2M (+100.0%) | 0.09% +0.087 pp | 0.10% +0.102 pp | USD48.48 +0.0% | 1 qtrs NEW |
| 75 | RHUMBLINE ADVISERS | 25.0K -4.2K (-14.4%) | 1.21M +318.1K (+35.5%) | 0.09% -0.015 pp | 0.00% +0.000 pp | USD41.38 +17.2% | 34 qtrs — |
| 76 | SCHONFELD STRATEGIC ADVISORS LLC | 24.4K +24.4K (+100.0%) | 1.18M +1.2M (+100.0%) | 0.08% +0.084 pp | 0.01% +0.005 pp | USD48.48 +0.0% | 1 qtrs NEW |
| 77 | QUADRATURE CAPITAL LTD | 24.3K +24.3K (+100.0%) | 1.18M +1.2M (+100.0%) | 0.08% +0.084 pp | 0.01% +0.012 pp | USD48.48 +0.0% | 1 qtrs NEW |
| 78 | MACKENZIE FINANCIAL CORP | 24.2K +24.2K (+100.0%) | 1.17M +1.2M (+100.0%) | 0.08% +0.083 pp | 0.00% +0.001 pp | USD48.48 +0.0% | 1 qtrs NEW |
| 79 | NEOS INVESTMENT MANAGEMENT LLC | 22.9K +11.9K (+108.6%) | 1.11M +773.9K (+230.3%) | 0.08% +0.041 pp | 0.01% +0.004 pp | USD35.88 +35.1% | 3 qtrs — |
| 80 | TEMA ETFS LLC | 22.6K +11.6K (+105.6%) | 1.09M +757.7K (+225.5%) | 0.08% +0.040 pp | 0.08% +0.057 pp | USD35.70 +35.8% | 3 qtrs — |
| 81 | WELLS FARGO & COMPANY/MN | 22.2K +8.5K (+61.6%) | 1.08M +655.8K (+155.8%) | 0.08% +0.029 pp | 0.00% +0.000 pp | USD32.59 +48.8% | 36 qtrs — |
| 82 | PANAGORA ASSET MANAGEMENT INC | 20.9K -43.0K (-67.3%) | 1.01M -943.4K (-48.2%) | 0.07% -0.150 pp | 0.00% -0.004 pp | USD26.22 +84.9% | 3 qtrs — |
| 83 | RUSSELL INVESTMENTS GROUP, LTD. | 19.7K -14.3K (-42.1%) | 955.8K -86.3K (-8.3%) | 0.07% -0.050 pp | 0.00% 0.000 pp | USD24.73 +96.0% | 33 qtrs — |
| 84 | LEGAL & GENERAL GROUP PLC | 18.2K -1.3K (-6.8%) | 881.4K +284.2K (+47.6%) | 0.06% -0.005 pp | 0.00% +0.000 pp | USD29.83 +62.5% | 36 qtrs — |
| 85 | TUDOR INVESTMENT CORP ET AL | 17.3K +3.4K (+24.8%) | 838.9K +414.3K (+97.6%) | 0.06% +0.011 pp | 0.00% +0.001 pp | USD35.33 +37.2% | 6 qtrs — |
| 86 | ALGERT GLOBAL LLC | 16.4K -67.4K (-80.4%) | 795.0K -1.8M (-69.0%) | 0.06% -0.234 pp | 0.01% -0.031 pp | USD30.62 +58.3% | 4 qtrs — |
| 87 | CREATIVE PLANNING | 15.3K -1.5K (-8.7%) | 739.5K +227.9K (+44.6%) | 0.05% -0.006 pp | 0.00% +0.000 pp | USD19.35 +150.5% | 4 qtrs — |
| 88 | CRESSET ASSET MANAGEMENT, LLC | 15.1K -632.0 (-4.0%) | 733.1K +250.7K (+52.0%) | 0.05% -0.003 pp | 0.00% +0.001 pp | USD20.67 +134.5% | 7 qtrs — |
| 89 | BRINKER CAPITAL INVESTMENTS, LLC | 14.7K +958.0 (+7.0%) | 712.5K +291.8K (+69.4%) | 0.05% +0.003 pp | 0.01% +0.002 pp | USD31.78 +52.5% | 2 qtrs — |
| 90 | DEUTSCHE BANK AG\ | 14.4K +1.7K (+13.4%) | 697.2K +308.9K (+79.6%) | 0.05% +0.006 pp | 0.00% +0.000 pp | USD23.61 +105.3% | 36 qtrs — |
| 91 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 14.1K -77.0 (-0.5%) | 685.4K +250.1K (+57.5%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD29.68 +63.3% | 36 qtrs — |
| 92 | PROFUND ADVISORS LLC | 13.1K +6.5K (+99.4%) | 634.5K +433.5K (+215.7%) | 0.05% +0.022 pp | 0.02% +0.013 pp | USD39.52 +22.7% | 2 qtrs — |
| 93 | VOYA INVESTMENT MANAGEMENT LLC | 12.8K -201.0 (-1.6%) | 618.6K +221.7K (+55.9%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD18.59 +160.8% | 6 qtrs — |
| 94 | LOS ANGELES CAPITAL MANAGEMENT LLC | 15.1K +225.0 (+1.5%) | 550.7K +95.2K (+20.9%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD22.59 +114.6% | 3 qtrs — |
| 95 | JPMORGAN CHASE & CO | 10.9K -3.9K (-26.5%) | 529.2K +74.4K (+16.4%) | 0.04% -0.014 pp | 0.00% +0.000 pp | USD21.96 +120.8% | 36 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 107 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Biotechnology & Genome ETF PBE | 2.80% | 8.01M | 0.58% |
| 2 | Franklin Small Cap Enhanced ETF FSML | 1.09% | 1.62M | 0.45% |
| 3 | Tema Oncology ETF CANC | 1.08% | 1.53M | 0.75% |
| 4 | Franklin Genomic Advancements ETF HELX | 1.01% | 305.1K | 0.50% |
| 5 | Virtus Biotech Clinical Trials ETF BBC | 0.73% | 419.5K | 0.65% |
| 6 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.56% | 1.59M | 0.39% |
| 7 | Global X - S&P Biotech ETF CURE.AX | 0.49% | 174.3K | 0.45% |
| 8 | State Street SPDR S&P Biotech ETF XBI | 0.48% | 52.36M | 0.35% |
| 9 | First Trust Active Factor Small Cap ETF AFSM | 0.44% | 492.6K | 0.75% |
| 10 | First Trust Small Cap Core AlphaDEX Fund FYX | 0.31% | 4.26M | 0.58% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
1.00
Neutral
Buys
33
Sells
33
Shares acquired
1.32M
Shares disposed
1.32M
Cash buys
—
Cash sales
—
Net activity
+250
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | GRAY SUSANNAH | Director | A-Award | A | Restricted Stock Unit | 11,250 | 0.00 | — | 11,250 | D | ↗ |
| 2026-04-20 | Schmid John P. | Director | A-Award | A | Stock Option (right to buy) | 16,510 | 10.87 | 179.5K | 16,510 | D | ↗ |
| 2026-04-20 | RENTON HOLLINGS | Director | D-Return | D | Stock Option (right to buy) | 5,500 | 43.91 | 241.5K | 5,500 | D | ↗ |
| 2026-04-20 | Orwin John A | Director | A-Award | A | Stock Option (right to buy) | 10,600 | 14.29 | 151.5K | 10,600 | D | ↗ |
| 2026-04-20 | Faga Daniel | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 379,620 | 15.53 | 5.90M | 379,620 | D | ↗ |
| 2026-03-30 | Schmid John P. | Director | S-Sale | D | Common Stock | 12,596 | 55.71 | 701.7K | 39,671 | D | ↗ |
| 2026-03-27 | Faga Daniel | Director / Officer | S-Sale | D | Common Stock | 3,662 | 58.62 | 214.7K | 506,902 | D | ↗ |
| 2026-03-26 | GRAY SUSANNAH | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-25 | Faga Daniel | Director / Officer | A-Award | A | Common Stock | 34,300 | 0.00 | — | 513,644 | D | ↗ |
| 2026-02-11 | LOUMEAU ERIC J | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 10,000 | 29.70 | 297.0K | 35,000 | D | ↗ |
| 2026-01-15 | Marquet Magda | Director | M-Exempt | A | Common Stock | 11,000 | 26.11 | 287.2K | 20,930 | D | ↗ |
| 2026-01-08 | MULROY DENNIS | Officer | S-Sale | D | Common Stock | 2,515 | 44.71 | 112.4K | 21,852 | D | ↗ |
| 2026-01-08 | Lizzul Paul F. | Officer | S-Sale | D | Common Stock | 3,650 | 44.71 | 163.2K | 42,088 | D | ↗ |
| 2026-01-08 | LOUMEAU ERIC J | Officer | S-Sale | D | Common Stock | 2,210 | 44.71 | 98.8K | 12,835 | D | ↗ |
| 2026-01-08 | Faga Daniel | Director / Officer | S-Sale | D | Common Stock | 14,281 | 44.71 | 638.5K | 479,344 | D | ↗ |
| 2026-01-07 | MULROY DENNIS | Officer | S-Sale | D | Common Stock | 1,908 | 45.11 | 86.1K | 17,667 | D | ↗ |
| 2026-01-07 | Lizzul Paul F. | Officer | S-Sale | D | Common Stock | 2,235 | 45.11 | 100.8K | 37,213 | D | ↗ |
| 2026-01-07 | LOUMEAU ERIC J | Officer | S-Sale | D | Common Stock | 500 | 47.23 | 23.6K | 9,157 | D | ↗ |
| 2026-01-07 | Faga Daniel | Director / Officer | S-Sale | D | Common Stock | 9,202 | 45.11 | 415.1K | 466,787 | D | ↗ |
| 2026-01-06 | Ware J. Anthony | Director | A-Award | A | Stock Option (right to buy) | 5,500 | 43.91 | 241.5K | 5,500 | D | ↗ |
| 2026-01-06 | Schmid John P. | Director | A-Award | A | Restricted Stock Unit | 4,000 | 0.00 | — | 4,000 | D | ↗ |
| 2026-01-06 | RENTON HOLLINGS | Director | A-Award | A | Stock Option (right to buy) | 5,500 | 43.91 | 241.5K | 5,500 | D | ↗ |
| 2026-01-06 | Orwin John A | Director | A-Award | A | Stock Option (right to buy) | 8,250 | 43.91 | 362.3K | 8,250 | D | ↗ |
| 2026-01-06 | Marquet Magda | Director | A-Award | A | Stock Option (right to buy) | 5,500 | 43.91 | 241.5K | 5,500 | D | ↗ |
| 2026-01-06 | MULROY DENNIS | Officer | M-Exempt | D | Restricted Stock Unit | 5,245 | 0.00 | — | 5,245 | D | ↗ |
| 2026-01-06 | Lizzul Paul F. | Officer | M-Exempt | D | Restricted Stock Unit | 6,145 | 0.00 | — | 6,145 | D | ↗ |
| 2026-01-06 | LOUMEAU ERIC J | Officer | A-Award | A | Stock Option (right to buy) | 23,200 | 43.91 | 1.02M | 23,200 | D | ↗ |
| 2026-01-06 | Jain Rita | Director | A-Award | A | Stock Option (right to buy) | 5,500 | 43.91 | 241.5K | 5,500 | D | ↗ |
| 2026-01-06 | Faga Daniel | Director / Officer | M-Exempt | A | Common Stock | 17,850 | 0.00 | — | 475,989 | D | ↗ |
| 2026-01-06 | FENTON DENNIS M | Director | A-Award | A | Restricted Stock Unit | 4,000 | 0.00 | — | 4,000 | D | ↗ |
| 2026-01-05 | MULROY DENNIS | Officer | S-Sale | D | Common Stock | 3,363 | 43.26 | 145.5K | 14,330 | D | ↗ |
| 2026-01-05 | Lizzul Paul F. | Officer | S-Sale | D | Common Stock | 4,219 | 43.26 | 182.5K | 33,303 | D | ↗ |
| 2026-01-05 | LOUMEAU ERIC J | Officer | S-Sale | D | Common Stock | 2,983 | 43.26 | 129.0K | 13,251 | D | ↗ |
| 2026-01-05 | Faga Daniel | Director / Officer | S-Sale | D | Common Stock | 15,309 | 43.26 | 662.3K | 458,139 | D | ↗ |
| 2026-01-03 | MULROY DENNIS | Officer | M-Exempt | D | Restricted Stock Unit | 8,292 | 0.00 | — | 16,585 | D | ↗ |
| 2026-01-03 | Lizzul Paul F. | Officer | M-Exempt | D | Restricted Stock Unit | 10,555 | 0.00 | — | 21,110 | D | ↗ |
| 2026-01-03 | LOUMEAU ERIC J | Officer | M-Exempt | D | Restricted Stock Unit | 7,287 | 0.00 | — | 14,575 | D | ↗ |
| 2026-01-03 | Faga Daniel | Director / Officer | M-Exempt | D | Restricted Stock Unit | 34,677 | 0.00 | — | 69,355 | D | ↗ |
| 2025-12-23 | Ware J. Anthony | Director | S-Sale | D | Common Stock | 3,900 | 49.58 | 193.3K | 9,630 | D | ↗ |
| 2025-12-23 | Schmid John P. | Director | J-Other | D | Common Stock | 11,068 | 51.00 | 564.5K | 0 | I | ↗ |
| 2025-12-22 | MULROY DENNIS | Officer | M-Exempt | A | Common Stock | 10,000 | 20.16 | 201.6K | 19,401 | D | ↗ |
| 2025-12-22 | Lizzul Paul F. | Officer | S-Sale | D | Common Stock | 1,500 | 50.00 | 75.0K | 26,967 | D | ↗ |
| 2025-12-22 | LOUMEAU ERIC J | Officer | S-Sale | D | Common Stock | 10,000 | 51.00 | 510.0K | 8,947 | D | ↗ |
| 2025-12-18 | LOUMEAU ERIC J | Officer | S-Sale | D | Common Stock | 141 | 46.99 | 6.6K | 8,947 | D | ↗ |
| 2025-12-17 | LOUMEAU ERIC J | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 10,000 | 14.02 | 140.2K | 53,000 | D | ↗ |
| 2025-12-16 | MULROY DENNIS | Officer | S-Sale | D | Common Stock | 9,365 | 44.62 | 417.8K | 15,761 | D | ↗ |
| 2025-12-16 | LOUMEAU ERIC J | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 7,500 | 20.16 | 151.2K | 0 | D | ↗ |
| 2025-09-30 | LOUMEAU ERIC J | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,000 | 14.02 | 70.1K | 68,000 | D | ↗ |
| 2025-09-15 | Orwin John A | Director | M-Exempt | A | Common Stock | 1,300 | 0.00 | — | 10,665 | D | ↗ |
| 2025-08-08 | RENTON HOLLINGS | Director | M-Exempt | A | Common Stock | 10,231 | 6.93 | 70.9K | 15,196 | D | ↗ |
| 2025-07-02 | RENTON HOLLINGS | Director | M-Exempt | A | Common Stock | 20,925 | 6.93 | 145.0K | 25,890 | D | ↗ |
| 2025-06-18 | RENTON HOLLINGS | Director | S-Sale | D | Common Stock | 3,015 | 23.97 | 72.3K | 4,965 | D | ↗ |
| 2025-06-18 | FENTON DENNIS M | Director | S-Sale | D | Common Stock | 3,015 | 23.97 | 72.3K | 4,965 | D | ↗ |
| 2025-06-15 | Ware J. Anthony | Director | M-Exempt | D | Restricted Stock Unit | 6,030 | 0.00 | — | 0 | D | ↗ |
| 2025-06-15 | Schmid John P. | Director | M-Exempt | D | Restricted Stock Unit | 6,030 | 0.00 | — | 0 | D | ↗ |
| 2025-06-15 | RENTON HOLLINGS | Director | M-Exempt | D | Restricted Stock Unit | 6,030 | 0.00 | — | 0 | D | ↗ |
| 2025-06-15 | Orwin John A | Director | M-Exempt | A | Common Stock | 6,030 | 0.00 | — | 9,365 | D | ↗ |
| 2025-06-15 | Marquet Magda | Director | M-Exempt | D | Restricted Stock Unit | 6,030 | 0.00 | — | 0 | D | ↗ |
| 2025-06-15 | Jain Rita | Director | M-Exempt | A | Common Stock | 7,330 | 0.00 | — | 11,864 | D | ↗ |
| 2025-06-15 | FENTON DENNIS M | Director | M-Exempt | D | Restricted Stock Unit | 6,030 | 0.00 | — | 0 | D | ↗ |
| 2025-03-25 | Schmid John P. | Director | J-Other | A | Common Stock | 11,068 | 18.18 | 201.2K | 11,068 | I | ↗ |
| 2025-01-13 | Schmid John P. | Director | M-Exempt | D | Stock Option (right to buy) | 20,645 | 8.54 | 176.3K | 0 | D | ↗ |
| 2025-01-07 | Ware J. Anthony | Director | A-Award | A | Stock Option (right to buy) | 16,510 | 14.83 | 244.8K | 16,510 | D | ↗ |
| 2025-01-07 | Schmid John P. | Director | A-Award | A | Stock Option (right to buy) | 16,510 | 14.83 | 244.8K | 16,510 | D | ↗ |
| 2025-01-07 | RENTON HOLLINGS | Director | A-Award | A | Stock Option (right to buy) | 16,510 | 14.83 | 244.8K | 16,510 | D | ↗ |
| 2025-01-07 | Orwin John A | Director | A-Award | A | Stock Option (right to buy) | 16,510 | 14.83 | 244.8K | 16,510 | D | ↗ |
| 2025-01-07 | Marquet Magda | Director | A-Award | A | Stock Option (right to buy) | 16,510 | 14.83 | 244.8K | 16,510 | D | ↗ |
| 2025-01-07 | MULROY DENNIS | Officer | A-Award | A | Stock Option (right to buy) | 76,400 | 14.83 | 1.13M | 76,400 | D | ↗ |
| 2025-01-07 | Lizzul Paul F. | Officer | A-Award | A | Stock Option (right to buy) | 97,200 | 14.83 | 1.44M | 97,200 | D | ↗ |
| 2025-01-07 | LOUMEAU ERIC J | Officer | A-Award | A | Stock Option (right to buy) | 67,000 | 14.83 | 993.6K | 67,000 | D | ↗ |
| 2025-01-07 | Jain Rita | Director | A-Award | A | Stock Option (right to buy) | 16,510 | 14.83 | 244.8K | 16,510 | D | ↗ |
| 2025-01-07 | Faga Daniel | Director / Officer | A-Award | A | Stock Option (right to buy) | 305,500 | 14.83 | 4.53M | 305,500 | D | ↗ |
| 2025-01-07 | FENTON DENNIS M | Director | A-Award | A | Stock Option (right to buy) | 16,510 | 14.83 | 244.8K | 16,510 | D | ↗ |
| 2025-01-06 | MULROY DENNIS | Officer | M-Exempt | A | Common Stock | 5,245 | 0.00 | — | 15,856 | D | ↗ |
| 2025-01-06 | Lizzul Paul F. | Officer | M-Exempt | A | Common Stock | 6,145 | 0.00 | — | 27,904 | D | ↗ |
| 2025-01-06 | LOUMEAU ERIC J | Officer | F-InKind | D | Common Stock | 2,217 | 15.30 | 33.9K | 11,003 | D | ↗ |
| 2025-01-06 | Faga Daniel | Director / Officer | F-InKind | D | Common Stock | 6,387 | 15.30 | 97.7K | 436,466 | D | ↗ |
| 2025-01-03 | MULROY DENNIS | Officer | M-Exempt | D | Restricted Stock Unit | 8,293 | 0.00 | — | 24,877 | D | ↗ |
| 2025-01-03 | Lizzul Paul F. | Officer | F-InKind | D | Common Stock | 4,336 | 14.60 | 63.3K | 21,759 | D | ↗ |
| 2025-01-03 | LOUMEAU ERIC J | Officer | M-Exempt | D | Restricted Stock Unit | 7,288 | 0.00 | — | 21,862 | D | ↗ |
| 2025-01-03 | Faga Daniel | Director / Officer | M-Exempt | A | Common Stock | 34,678 | 0.00 | — | 438,036 | D | ↗ |
| 2025-01-02 | EcoR1 Capital, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 6,646 | 12.95 | 86.1K | 7,880,094 | I | ↗ |
| 2024-12-31 | EcoR1 Capital, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 13,268 | 12.93 | 171.5K | 7,873,448 | I | ↗ |
| 2024-12-30 | EcoR1 Capital, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 65,184 | 12.92 | 842.1K | 7,860,180 | I | ↗ |
| 2024-11-29 | RENTON HOLLINGS | Director | M-Exempt | D | Common Stock | 10,000 | 6.93 | 69.3K | 20,925 | D | ↗ |
| 2024-09-23 | Lizzul Paul F. | Officer | M-Exempt | D | Common | 1,500 | 18.50 | 27.8K | 85,000 | D | ↗ |
| 2024-09-17 | LOUMEAU ERIC J | Officer | S-Sale | D | Common Stock | 3,780 | 38.41 | 145.2K | 3,240 | — | ↗ |
| 2024-09-16 | MULROY DENNIS | Officer | S-Sale | D | Common Stock | 2,220 | 38.93 | 86.4K | 4,744 | — | ↗ |
| 2024-09-16 | Lizzul Paul F. | Officer | S-Sale | D | Common Stock | 2,220 | 38.93 | 86.4K | 15,398 | — | ↗ |
| 2024-09-16 | LOUMEAU ERIC J | Officer | S-Sale | D | Common Stock | 2,220 | 38.93 | 86.4K | 8,520 | — | ↗ |
| 2024-09-15 | Orwin John A | Director | M-Exempt | A | Common Stock | 1,300 | 0.00 | — | 3,335 | — | ↗ |
| 2024-09-14 | MULROY DENNIS | Officer | M-Exempt | A | Common Stock | 6,000 | 0.00 | — | 6,964 | — | ↗ |
| 2024-09-14 | Lizzul Paul F. | Officer | M-Exempt | D | Restricted Stock Unit | 6,000 | 0.00 | — | 0 | — | ↗ |
| 2024-09-14 | LOUMEAU ERIC J | Officer | M-Exempt | A | Common Stock | 6,000 | 0.00 | — | 10,740 | — | ↗ |
| 2024-08-14 | Lizzul Paul F. | Officer | S-Sale | D | Common Stock | 2,000 | 40.00 | 80.0K | 11,618 | — | ↗ |
| 2024-08-14 | EcoR1 Capital, LLC | 10% Owner | P-Purchase | A | Common Stock | 273,972 | 36.50 | 10.00M | 7,794,996 | — | ↗ |
| 2024-07-22 | MULROY DENNIS | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2024-07-22 | Lizzul Paul F. | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2024-07-22 | LOUMEAU ERIC J | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2024-07-22 | Faga Daniel | Director / Officer | A-Award | A | Common Stock | 160,000 | 0.00 | — | 160,000 | — | ↗ |
| 2024-07-18 | Lizzul Paul F. | Officer | M-Exempt | D | Common | 1,500 | 18.50 | 27.8K | 88,500 | — | ↗ |
| 2024-07-15 | RENTON HOLLINGS | Director | M-Exempt | A | Common Stock | 10,000 | 6.93 | 69.3K | 11,950 | — | ↗ |
| 2024-06-21 | FENTON DENNIS M | Director | S-Sale | D | Common Stock | 1,950 | 23.17 | 45.2K | 1,950 | — | ↗ |
| 2024-06-18 | RENTON HOLLINGS | Director | S-Sale | D | Common Stock | 1,950 | 23.16 | 45.2K | 1,950 | — | ↗ |
| 2024-06-15 | Ware J. Anthony | Director | M-Exempt | D | Restricted Stock Unit | 3,900 | 0.00 | — | 0 | — | ↗ |
| 2024-06-15 | Schmid John P. | Director | M-Exempt | D | Restricted Stock Unit | 3,900 | 0.00 | — | 0 | — | ↗ |
| 2024-06-15 | RENTON HOLLINGS | Director | M-Exempt | D | Restricted Stock Unit | 3,900 | 0.00 | — | 0 | — | ↗ |
| 2024-06-15 | Orwin John A | Director | M-Exempt | D | Restricted Stock Unit | 2,035 | 0.00 | — | 0 | — | ↗ |
| 2024-06-15 | Marquet Magda | Director | M-Exempt | D | Restricted Stock Unit | 3,900 | 0.00 | — | 0 | — | ↗ |
| 2024-06-15 | Jain Rita | Director | M-Exempt | D | Restricted Stock Unit | 1,300 | 0.00 | — | 0 | — | ↗ |
| 2024-06-15 | FENTON DENNIS M | Director | M-Exempt | D | Restricted Stock Unit | 3,900 | 0.00 | — | 0 | — | ↗ |
| 2024-05-22 | MULROY DENNIS | Officer | S-Sale | D | Common Stock | 1,500 | 23.72 | 35.6K | 964 | — | ↗ |
| 2024-03-26 | Faga Daniel | Director / Officer | F-InKind | D | Common Stock | 347,441 | 21.60 | 7.50M | 401,646 | — | ↗ |
| 2024-03-25 | Faga Daniel | Director / Officer | S-Sale | D | Common Stock | 3,000 | 21.42 | 64.3K | 749,087 | — | ↗ |
| 2024-03-22 | Faga Daniel | Director / Officer | S-Sale | D | Common Stock | 145,940 | 22.78 | 3.33M | 752,087 | — | ↗ |
| 2024-02-16 | LOUMEAU ERIC J | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,000 | 14.02 | 70.1K | 78,000 | — | ↗ |
| 2024-01-30 | MULROY DENNIS | Officer | S-Sale | D | Common Stock | 3,065 | 23.63 | 72.4K | 964 | — | ↗ |
| 2024-01-08 | MULROY DENNIS | Officer | S-Sale | D | Common Stock | 2,180 | 21.81 | 47.5K | 4,029 | — | ↗ |
| 2024-01-08 | Lizzul Paul F. | Officer | S-Sale | D | Common Stock | 2,554 | 21.81 | 55.7K | 10,118 | — | ↗ |
| 2024-01-08 | LOUMEAU ERIC J | Officer | S-Sale | D | Common Stock | 2,305 | 21.81 | 50.3K | 3,240 | — | ↗ |
| 2024-01-08 | Faga Daniel | Director / Officer | S-Sale | D | Common Stock | 6,866 | 21.81 | 149.7K | 898,027 | — | ↗ |
| 2024-01-06 | MULROY DENNIS | Officer | M-Exempt | D | Restricted Stock Unit | 5,245 | 0.00 | — | 15,735 | — | ↗ |
| 2024-01-06 | Lizzul Paul F. | Officer | M-Exempt | A | Common Stock | 6,145 | 0.00 | — | 12,672 | — | ↗ |
| 2024-01-06 | LOUMEAU ERIC J | Officer | M-Exempt | A | Common Stock | 5,545 | 0.00 | — | 5,545 | — | ↗ |
| 2024-01-06 | Faga Daniel | Director / Officer | M-Exempt | D | Restricted Stock Unit | 17,850 | 0.00 | — | 53,550 | — | ↗ |
| 2024-01-03 | Ware J. Anthony | Director | A-Award | A | Restricted Stock Unit | 6,030 | 0.00 | — | 6,030 | — | ↗ |
| 2024-01-03 | Schmid John P. | Director | A-Award | A | Stock Option (right to buy) | 16,510 | 21.19 | 349.8K | 16,510 | — | ↗ |
| 2024-01-03 | RENTON HOLLINGS | Director | A-Award | A | Stock Option (right to buy) | 16,510 | 21.19 | 349.8K | 16,510 | — | ↗ |
| 2024-01-03 | Orwin John A | Director | A-Award | A | Restricted Stock Unit | 6,030 | 0.00 | — | 6,030 | — | ↗ |
| 2024-01-03 | Marquet Magda | Director | A-Award | A | Stock Option (right to buy) | 16,510 | 21.19 | 349.8K | 16,510 | — | ↗ |
| 2024-01-03 | MULROY DENNIS | Officer | A-Award | A | Restricted Stock Unit | 33,170 | 0.00 | — | 33,170 | — | ↗ |
| 2024-01-03 | Lizzul Paul F. | Officer | A-Award | A | Restricted Stock Unit | 42,220 | 0.00 | — | 42,220 | — | ↗ |
| 2024-01-03 | LOUMEAU ERIC J | Officer | A-Award | A | Restricted Stock Unit | 29,150 | 0.00 | — | 29,150 | — | ↗ |
| 2024-01-03 | Jain Rita | Director | A-Award | A | Restricted Stock Unit | 6,030 | 0.00 | — | 6,030 | — | ↗ |
| 2024-01-03 | Faga Daniel | Director / Officer | A-Award | A | Restricted Stock Unit | 138,710 | 0.00 | — | 138,710 | — | ↗ |
| 2024-01-03 | FENTON DENNIS M | Director | A-Award | A | Stock Option (right to buy) | 16,510 | 21.19 | 349.8K | 16,510 | — | ↗ |
| 2023-11-22 | LOUMEAU ERIC J | Officer | S-Sale | D | Common Stock | 882 | 14.19 | 12.5K | 0 | — | ↗ |
| 2023-09-18 | MULROY DENNIS | Officer | S-Sale | D | Common Stock | 3,895 | 19.32 | 75.2K | 964 | — | ↗ |
| 2023-09-18 | LOUMEAU ERIC J | Officer | S-Sale | D | Common Stock | 3,895 | 19.32 | 75.2K | 882 | — | ↗ |
| 2023-09-15 | Orwin John A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-09-14 | MULROY DENNIS | Officer | M-Exempt | D | Restricted Stock Unit | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2023-09-14 | Lizzul Paul F. | Officer | M-Exempt | D | Restricted Stock Unit | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2023-09-14 | LOUMEAU ERIC J | Officer | S-Sale | D | Common Stock | 2,105 | 19.48 | 41.0K | 4,777 | — | ↗ |
| 2023-04-03 | Jain Rita | Director | A-Award | A | Stock Option (right to buy) | 8,015 | 22.09 | 177.1K | 8,015 | — | ↗ |
| 2023-01-06 | Ware J. Anthony | Director | A-Award | A | Restricted Stock Unit | 3,900 | 0.00 | — | 3,900 | — | ↗ |
| 2023-01-06 | Topper James N | Director | A-Award | A | Stock Option (right to buy) | 10,600 | 0.00 | — | 10,600 | — | ↗ |
| 2023-01-06 | Schmid John P. | Director | A-Award | A | Restricted Stock Unit | 3,900 | 0.00 | — | 3,900 | — | ↗ |
| 2023-01-06 | RENTON HOLLINGS | Director | A-Award | A | Restricted Stock Unit | 3,900 | 0.00 | — | 3,900 | — | ↗ |
| 2023-01-06 | Marquet Magda | Director | A-Award | A | Restricted Stock Unit | 3,900 | 0.00 | — | 3,900 | — | ↗ |
| 2023-01-06 | MULROY DENNIS | Officer | A-Award | A | Restricted Stock Unit | 20,980 | 0.00 | — | 20,980 | — | ↗ |
| 2023-01-06 | Lizzul Paul F. | Officer | A-Award | A | Restricted Stock Unit | 24,580 | 0.00 | — | 24,580 | — | ↗ |
| 2023-01-06 | LOUMEAU ERIC J | Officer | A-Award | A | Stock Option (right to buy) | 60,530 | 0.00 | — | 60,530 | — | ↗ |
| 2023-01-06 | Hamill Laura | Director | A-Award | A | Restricted Stock Unit | 3,900 | 0.00 | — | 3,900 | — | ↗ |
| 2023-01-06 | Faga Daniel | Officer | A-Award | A | Restricted Stock Unit | 71,400 | 0.00 | — | 71,400 | — | ↗ |
| 2023-01-06 | FENTON DENNIS M | Director | A-Award | A | Restricted Stock Unit | 3,900 | 0.00 | — | 3,900 | — | ↗ |
| 2022-09-14 | MULROY DENNIS | Officer | A-Award | A | Restricted Stock Unit | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2022-09-14 | Lizzul Paul F. | Officer | A-Award | A | Restricted Stock Unit | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2022-09-14 | LOUMEAU ERIC J | Officer | A-Award | A | Restricted Stock Unit | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2022-08-08 | LOUMEAU ERIC J | Officer | S-Sale | D | Common Stock | 523 | 25.00 | 13.1K | 0 | — | ↗ |
| 2022-06-23 | MULROY DENNIS | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 29.70 | 297.0K | 10,000 | — | ↗ |
| 2022-06-23 | Lizzul Paul F. | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-23 | LOUMEAU ERIC J | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-08 | LOUMEAU ERIC J | Officer | M-Exempt | A | Common Stock | 2,500 | 14.02 | 35.1K | 3,023 | — | ↗ |
| 2022-05-18 | LOUMEAU ERIC J | Officer | S-Sale | D | Common Stock | 1,146 | 20.50 | 23.5K | 523 | — | ↗ |
| 2022-05-05 | NODELMAN OLEG | Director | P-Purchase | A | Common Stock | 668,237 | 21.63 | 14.45M | 7,521,024 | — | ↗ |
| 2022-05-05 | EcoR1 Capital, LLC | 10% Owner | P-Purchase | A | Common Stock | 668,237 | 21.63 | 14.45M | 7,521,024 | — | ↗ |
| 2022-03-21 | Faga Daniel | Officer | A-Award | A | Common Stock | 887,043 | 0.00 | — | 887,043 | — | ↗ |
| 2022-02-10 | Ware J. Anthony | Director | A-Award | A | Stock Option (right to buy) | 9,200 | 30.44 | 280.0K | 9,200 | — | ↗ |
| 2022-02-10 | Topper James N | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 9,200 | 30.44 | 280.0K | 9,200 | — | ↗ |
| 2022-02-10 | Suria Hamza | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 30.44 | 6.09M | 200,000 | — | ↗ |
| 2022-02-10 | Schmid John P. | Director | A-Award | A | Stock Option (right to buy) | 9,200 | 30.44 | 280.0K | 9,200 | — | ↗ |
| 2022-02-10 | RENTON HOLLINGS | Director | A-Award | A | Stock Option (right to buy) | 9,200 | 30.44 | 280.0K | 9,200 | — | ↗ |
| 2022-02-10 | Marquet Magda | Director | A-Award | A | Stock Option (right to buy) | 9,200 | 30.44 | 280.0K | 9,200 | — | ↗ |
| 2022-02-10 | MULROY DENNIS | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 30.44 | 2.13M | 70,000 | — | ↗ |
| 2022-02-10 | Lizzul Paul F. | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 30.44 | 2.13M | 70,000 | — | ↗ |
| 2022-02-10 | LOUMEAU ERIC J | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 30.44 | 2.13M | 70,000 | — | ↗ |
| 2022-02-10 | Hamill Laura | Director | A-Award | A | Stock Option (right to buy) | 9,200 | 30.44 | 280.0K | 9,200 | — | ↗ |
| 2022-02-10 | Faga Daniel | Director | A-Award | A | Stock Option (right to buy) | 9,200 | 30.44 | 280.0K | 9,200 | — | ↗ |
| 2022-02-10 | FENTON DENNIS M | Director | A-Award | A | Stock Option (right to buy) | 9,200 | 30.44 | 280.0K | 9,200 | — | ↗ |
| 2021-12-20 | Suria Hamza | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 36,645 | 1.12 | 41.0K | 0 | — | ↗ |
| 2021-11-26 | Faga Daniel | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 31.12 | 342.3K | 11,000 | — | ↗ |
| 2021-11-15 | Suria Hamza | Director / Officer | A-Award | A | Common Stock | 964 | 22.03 | 21.2K | 68,600 | — | ↗ |
| 2021-11-15 | MULROY DENNIS | Officer | A-Award | A | Common Stock | 964 | 22.03 | 21.2K | 964 | — | ↗ |
| 2021-11-15 | Lizzul Paul F. | Officer | A-Award | A | Common Stock | 964 | 22.03 | 21.2K | 964 | — | ↗ |
| 2021-11-15 | LOUMEAU ERIC J | Officer | A-Award | A | Common Stock | 523 | 22.03 | 11.5K | 523 | — | ↗ |
| 2021-11-05 | Suria Hamza | Director / Officer | M-Exempt | A | Common Stock | 14,302 | 1.12 | 16.0K | 81,938 | — | ↗ |
| 2021-11-04 | Suria Hamza | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 6,059 | 1.12 | 6.8K | 14,302 | — | ↗ |
| 2021-11-04 | LOUMEAU ERIC J | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 2,500 | 20.16 | 50.4K | 7,500 | — | ↗ |
| 2021-11-01 | Suria Hamza | Director / Officer | M-Exempt | A | Common Stock | 36,646 | 1.12 | 41.0K | 104,282 | — | ↗ |
| 2021-10-26 | Suria Hamza | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 15,993 | 1.12 | 17.9K | 73,291 | — | ↗ |
| 2021-09-17 | Suria Hamza | Director / Officer | M-Exempt | A | Common Stock | 10,000 | 1.12 | 11.2K | 67,636 | — | ↗ |
| 2021-05-12 | Suria Hamza | Director / Officer | M-Exempt | A | Common Stock | 10,000 | 1.12 | 11.2K | 57,636 | — | ↗ |
| 2021-05-04 | EcoR1 Capital, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 165,000 | 23.25 | 3.84M | 7,520,424 | — | ↗ |
| 2021-05-03 | EcoR1 Capital, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 20,800 | 23.31 | 484.9K | 7,355,424 | — | ↗ |
| 2021-04-30 | EcoR1 Capital, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 35,700 | 23.16 | 826.8K | 7,334,624 | — | ↗ |
| 2021-04-27 | EcoR1 Capital, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 33,800 | 23.82 | 805.1K | 7,298,924 | — | ↗ |
| 2021-04-26 | EcoR1 Capital, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 13,900 | 23.80 | 330.9K | 7,265,124 | — | ↗ |
| 2021-04-23 | EcoR1 Capital, LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 99,600 | 23.54 | 2.34M | 7,251,224 | — | ↗ |
| 2021-04-08 | NODELMAN OLEG | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 7,151,624 | — | ↗ |
| 2021-03-09 | EcoR1 Capital, LLC | 10% Owner | P-Purchase | A | Common Stock | 531,000 | 18.70 | 9.93M | 7,151,624 | — | ↗ |
Executive team
Top executives
EBIT / Employee
460.5K
Shares Outstanding
43.12M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Daniel Faga President and Chief Executive Officer and Director | 685.4K | — | 6.89M | 5.72M | 308.5K | 23.8K | 13.63M | 92.53% | ↗ |
| 2 | 2024 | Paul Lizzul Chief Medical Officer | 529.9K | — | 2.13M | 1.74M | 159.0K | 23.7K | 4.58M | 84.45% | ↗ |
| 3 | 2024 | Dennis Mulroy Chief Financial Officer | 495.2K | — | 1.20M | 1.37M | 148.6K | 29.9K | 3.24M | 79.20% | ↗ |
| 4 | 2023 | Daniel Faga President and Chief Executive Officer and Director | 640.6K | — | 1.66M | 3.29M | 352.3K | 1.52M | 7.46M | 66.28% | ↗ |
| 5 | 2023 | Paul Lizzul Chief Medical Officer | 509.5K | — | 571.0K | 1.13M | 203.8K | 25.6K | 2.44M | 69.73% | ↗ |
| 6 | 2023 | Eric Loumeau Chief Legal Officer | 493.8K | — | 515.2K | 1.02M | 197.5K | 30.7K | 2.26M | 68.03% | ↗ |
| 7 | 2023 | Dennis Mulroy Chief Financial Officer | 479.4K | — | 487.4K | 965.8K | 191.8K | 31.7K | 2.16M | 67.40% | ↗ |
| 8 | 2022 | Daniel Faga Interim President and Chief Executive Officer and Director | 483.6K | — | 23.51M | 200.6K | 240.6K | 8.9K | 24.44M | 97.00% | ↗ |
| 9 | 2022 | Daniel Faga President and Chief Executive Officer and Director | 483.6K | — | 23.51M | 200.6K | 240.6K | 8.9K | 24.44M | 97.00% | ↗ |
| 10 | 2022 | Hamza Suria Former President, Chief Executive Officer and Director | 672.8K | — | — | 6.57M | — | 5.5K | 7.25M | 90.65% | ↗ |
| 11 | 2022 | Eric Loumeau Chief Legal Officer | 474.8K | — | 283.4K | 2.87M | 197.6K | 13.1K | 3.84M | 82.15% | ↗ |
| 12 | 2022 | Eric Loumeau Chief Operating Officer and General Counsel | 474.8K | — | 283.4K | 2.87M | 197.6K | 13.1K | 3.84M | 82.15% | ↗ |
| 13 | 2022 | Paul Lizzul Chief Medical Officer | 471.7K | — | 283.4K | 2.87M | 174.5K | 10.1K | 3.81M | 82.78% | ↗ |
| 14 | 2021 | Hamza Suria Former President, Chief Executive Officer and Director | 586.0K | — | — | 3.73M | 274.0K | 8.8K | 4.60M | 81.12% | ↗ |
| 15 | 2021 | Hamza Suria President, Chief Executive Officer and Director | 586.0K | — | — | 2.70M | 241.7K | 8.8K | 3.54M | 76.36% | ↗ |
| 16 | 2021 | Eric Loumeau Chief Operating Officer and General Counsel | 461.0K | — | — | 1.46M | 176.3K | 10.3K | 2.11M | 69.29% | ↗ |
| 17 | 2021 | Paul Lizzul Chief Medical Officer | 458.0K | — | — | 1.46M | 155.7K | 8.8K | 2.08M | 70.13% | ↗ |
| 18 | 2020 | Dennis Mulroy Chief Financial Officer | 184.9K | — | — | 1.36M | 74.3K | 4.7K | 1.62M | 83.74% | ↗ |
| 19 | 2020 | Paul Lizzul Chief Medical Officer | 168.2K | — | — | 1.24M | 67.5K | 104.2K | 1.58M | 78.47% | ↗ |
| 20 | 2020 | Paul Lizzul, M.D., Ph.D., M.PH., M.B.A. Chief Medical Officer | 168.2K | — | — | 1.24M | 67.3K | 104.2K | 1.58M | 78.48% | ↗ |
| 21 | 2020 | Hamza Suria President, Chief Executive Officer and Director | 567.0K | — | — | — | 311.9K | 6.5K | 885.4K | 0.00% | ↗ |
| 22 | 2020 | Hamza Suria, M.B.A. President, Chief Executive Officer and Director | 567.0K | — | — | — | 311.9K | 6.5K | 885.4K | 0.00% | ↗ |
| 23 | 2020 | Eric Loumeau Chief Operating Officer and General Counsel | 399.0K | — | — | 150.0K | 168.0K | 8.3K | 725.3K | 20.68% | ↗ |
| 24 | 2019 | Hamza Suria, M.B.A. President, Chief Executive Officer and Director | 567.0K | — | — | 7.30M | — | 6.5K | 7.88M | 92.72% | ↗ |
| 25 | 2019 | Eric Loumeau, J.D. Interim Chief Financial Officer and General Counsel | 381.0K | — | — | 3.06M | 91.4K | 8.3K | 3.54M | 86.43% | ↗ |
| 26 | 2019 | Marco Londei, M.D. Former Chief Medical Officer | 453.0K | — | — | 2.53M | 108.7K | 9.6K | 3.10M | 81.56% | ↗ |
| 27 | 2019 | Dominic G. Piscitelli, M.B.A., C.P.A. Former Chief Financial Officer | 310.9K | — | — | 1.54M | — | 6.6K | 1.86M | 82.89% | ↗ |
| 28 | 2018 | Hamza Suria, M.B.A. President, Chief Executive Officer and Director | 547.0K | — | — | 4.30M | 270.8K | 540.00 | 5.12M | 84.02% | ↗ |
| 29 | 2018 | Marco Londei, M.D. Chief Medical Officer | 436.0K | — | — | 1.91M | 161.3K | 3.6K | 2.51M | 76.10% | ↗ |
| 30 | 2018 | Marco Londei, M.D. Former Chief Medical Officer | 436.0K | — | — | 1.91M | 161.3K | 3.6K | 2.51M | 76.10% | ↗ |
| 31 | 2018 | Eric Loumeau, J.D. Interim Chief Financial Officer and General Counsel | 148.1K | — | — | 1.96M | 54.8K | 774.00 | 2.17M | 90.59% | ↗ |
| 32 | 2018 | Eric Loumeau, J.D. General Counsel | 148.1K | — | — | 1.96M | 54.8K | 774.00 | 2.17M | 90.59% | ↗ |
| 33 | 2018 | Dominic Piscitelli, M.B.A., C.P.A. Chief Financial Officer | 397.0K | — | — | 1.57M | 146.9K | 540.00 | 2.12M | 74.27% | ↗ |
| 34 | 2018 | Dominic G. Piscitelli, M.B.A., C.P.A. Former Chief Financial Officer | 397.0K | — | — | 1.57M | 146.9K | 540.00 | 2.12M | 74.27% | ↗ |
| 35 | 2017 | Hamza Suria, M.B.A. President, Chief Executive Officer and Director | 465.0K | — | — | 3.34M | 209.3K | 600.00 | 4.02M | 83.20% | ↗ |
| 36 | 2017 | Dominic Piscitelli, M.B.A., C.P.A. Chief Financial Officer | 356.8K | 100.0K | — | 2.29M | 111.1K | 13.3K | 2.87M | 79.76% | ↗ |
| 37 | 2017 | Dominic G. Piscitelli, M.B.A., C.P.A. Former Chief Financial Officer | 356.8K | 100.0K | — | 2.29M | 111.1K | 13.3K | 2.87M | 79.76% | ↗ |
| 38 | 2017 | Marco Londei, M.D. Former Chief Medical Officer | 395.3K | — | — | 1.63M | 118.0K | 4.0K | 2.15M | 75.95% | ↗ |
| 39 | 2017 | Marco Londei, M.D. Chief Medical Officer | 395.3K | — | — | 1.63M | 118.0K | 4.0K | 2.15M | 75.95% | ↗ |
| 40 | 2017 | Matthew Moyle, Ph.D. Chief Scientific Officer | 183.0K | — | — | — | — | 143.7K | 326.7K | 0.00% | ↗ |
| 41 | 2016 | Matthew Moyle, Ph.D. Chief Scientific Officer | 181.3K | 44.4K | — | 614.5K | — | 37.7K | 877.9K | 70.00% | ↗ |
| 42 | 2016 | Hamza Suria, M.B.A. President, Chief Executive Officer and Director | 425.0K | 153.0K | — | — | — | 600.00 | 578.6K | 0.00% | ↗ |
| 43 | 2016 | Marco Londei, M.D. Chief Medical Officer | 380.0K | 92.3K | — | — | — | 11.9K | 484.3K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel R. Faga | President, Chief Executive Officer & Director | 1M | male |
| Paul F. Lizzul FAAD | Chief Medical Officer | 795.2K | — |
| Eric J. Loumeau | Chief Legal Officer | 722.0K | male |
| Dennis Mulroy | Chief Financial Officer | 673.6K | male |
| John Kwon | Vice President of GI Clinical Development | — | — |
| Martin Dahl | Senior Vice President of Research | — | — |
| Monique Da Silva | Senior Vice President of Corporate Affairs | — | female |
| Benjamin Stone | Chief Business Officer | — | male |
| Priya Raina | Senior Vice President of Clinical Operations | — | female |
| Beth Mueller | Senior Vice President of Human Resources | — | female |
| Cailin Sibley FACR | Senior Vice President of Translational Medicine | — | female |
| David McKeon | Senior Vice President & Controller | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANAB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
